Evidence map›Paper›PMID 31690107›Full record

ArticleClinical trials (London, England)2020

Nonparticipation reasons in a randomized international trial of a new latent tuberculosis infection regimen.

Kimberley N Chapman Hedges, Andrey S Borisov, Jussi J Saukkonen, Nigel A Scott, Emily J Hecker, Lorna Bozeman, Carol Dukes Hamilton, Amy Kerrigan, Patricia Bessler, Antonio Moreno-Martinez and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Clinical trials (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Reasons for acceptance or nonparticipation in iAdhere: a trial of latent TB infection treatment.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 2 countries.

Kimberley N Chapman HedgesCenters for Disease Control and Prevention, Atlanta, GA, USA.ORCID 0000-0002-0925-4053
Andrey S BorisovCenters for Disease Control and Prevention, Atlanta, GA, USA.
Jussi J SaukkonenSchool of Medicine, Boston University, Boston, MA, USA.
Nigel A ScottCenters for Disease Control and Prevention, Atlanta, GA, USA.
Emily J HeckerSchool of Medicine, Duke University, Durham, NC, USA.
Lorna BozemanCenters for Disease Control and Prevention, Atlanta, GA, USA.
Carol Dukes HamiltonSchool of Medicine, Duke University, Durham, NC, USA.
Amy KerriganSchool of Medicine, Vanderbilt University, Nashville, TN, USA.
Patricia BesslerCenters for Disease Control and Prevention, Atlanta, GA, USA.
Antonio Moreno-MartinezCIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.
Bert ArevaloWestat, Rockville, MD, USA.
Stefan V GoldbergCenters for Disease Control and Prevention, Atlanta, GA, USA.
Centers for Disease Control and Prevention · USBoston University · USCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública · ESDuke University · USFamily Health International 360 · USVanderbilt University · USWestat (United States) · US

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

BACKGROUND/

aimsEfficient recruitment of eligible participants, optimizing time and sample size, is a crucial component in conducting a successful clinical trial. Inefficient participant recruitment can impede study progress, consume staff time and resources, and limit quality and generalizability or the power to assess outcomes. Recruitment for disease prevention trials poses additional challenges because patients are asymptomatic. We evaluated candidates for a disease prevention trial to determine reasons for nonparticipation and to identify factors that can be addressed to improve recruitment efficiency.

methodsDuring 2001-2009, the Tuberculosis Trials Consortium conducted Study 26 (PREVENT TB), a randomized clinical trial at 26 sites in four countries, among persons with latent tuberculosis infection at high risk for tuberculosis disease progression, comparing 3 months of directly observed once-weekly rifapentine plus isoniazid with 9 months of self-administered daily isoniazid. During March 2005-February 2008, non-identifying demographic information, risk factors for experiencing active tuberculosis disease, and reasons for not enrolling were collected from screened patients to facilitate interpretation of trial data, to meet Consolidated Standards of Reporting Trials standards, and to evaluate reasons for nonparticipation.

resultsOf the 7452 candidates screened in Brazil, Canada, Spain, and the United States, 3584 (48%) were not enrolled, because of ineligibility (41%), site decision (10%), or patient choice (49%). Among those who did not enroll by own choice, and for whom responses were recorded on whether they would accept treatment outside of the study (n = 1430), 68% reported that they planned to accept non-study latent tuberculosis infection treatment. Among 1305 patients with one or more reported reasons for nonparticipation, study staff recorded a total of 1886 individual reasons (reason count: median = 1/patient; range = 1-9) for why patients chose not to enroll, including grouped concerns about research (24% of 1886), work or school conflicts (20%), medication or health beliefs (16%), latent tuberculosis infection beliefs (11%), and patient lifestyle and family concerns (10%).

conclusionEducational efforts addressing clinical research concerns and beliefs about medication and health, as well as study protocols that accommodate patient-related concerns (e.g. work, school, and lifestyle) might increase willingness to enter clinical trials. Findings from this evaluation can support development of communication and education materials for clinical trial sites at the beginning of a trial to allow study staff to address potential participant concerns during study screening.

Indexed as

Patient SelectionRefusal to ParticipateAdolescentAdultAntitubercular AgentsChildChild, PreschoolClinical Trials, Phase III as TopicDrug Therapy, CombinationFemaleHumansIsoniazidLatent TuberculosisMaleRandomized Controlled Trials as TopicRifampinAntitubercular AgentsIsoniazidRifampinrifapentineclinical trialsLatent tuberculosispatient selectionrecruitment

Identifiers

PMID31690107
PMCPMC9446162
OpenAlexW2984316440

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.